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Abstract
Background: Anecdotal reports suggests that most clinicians treat medications as belonging to a class with regard
to all therapeutic indications; this means that the whole ‘class’ of drugs is considered to possesses a specific
therapeutic action. The present article explores the possible existence of a true ‘class effect’ for agents available for
the treatment of bipolar disorder.
Methods: We reviewed the available treatment data from randomized controlled trials (RCTs) and explored 16
‘agent class’/’treatment issue’ cases for bipolar disorder. Four classes of agents were examined: first-generation
antipsychotics (FGAs), second-generation antipsychotics (SGAs), antiepileptics and antidepressants, with respect to
their efficacy on four treatment issues of bipolar disorder (BD) (acute mania, acute bipolar depression, maintenance
against mania, maintenance against depression).
Results: From the 16 ‘agent class’/’ treatment issue’ cases, only 3 possible class effects were detected, and they all
concerned acute mania and antipsychotics. Four effect cases have not been adequately studied (FGAs against
acute bipolar depression and in maintenance protection from depression, and antidepressants against acute mania
and protection from mania) and they all concern treatment cases with a high risk of switching to the opposite
pole, thus research in these areas is poor. There is no ‘class effect’ at all concerning antiepileptics.
Conclusions: The available data suggest that a ‘class effect’ is the exception rather than the rule in the treatment
of BD. However, the possible presence of a ‘class effect’ concept discourages clinicians from continued scientific
training and reading. Focused educational intervention might be necessary to change this attitude.
Background
In the last decade there were important developments in
our understanding of bipolar disorder (BD), as well as its
treatment. From a historical point of view, since Hippo-
crates from antiquity to Emil Kraepelin in the early 20th
century, manic depressive illness has been established as
a nosological entity (and separate from schizophrenia) on
the basis of heredity, longitudinal follow-up and a sup-
posed favorable outcome. However, recently there was
important insight into the illness with the description
and definition of subtypes (BD-I to BD-VI) [1-3].
This dramatically changed the perceived epidemiology
of the disorder. Although earlier studies suggested that
the classic manic depressive psychosis had a prevalence
of around 1% (0.4% to 1.6%), today we know that the true
prevalence depends on the definition, and with the inclu-
sion of subthreshold bipolar cases, pseudounipolar
patients and personality disorders (PDs), especially ‘bor-
derline personality disorder’ under the umbrella of the
‘bipolar spectrum’, the combined prevalence rate is up to
3.7%, with BD-II being the most prevalent subtype [4-6].
Similarly, our knowledge and understanding of treat-
ment has progressed, largely following our understand-
ing of the clinical picture. The first dramatic conclusion
was that the outcome of bipolar illness is not favorable
as Kraepelin had determined, but rather suboptimal and
is strongly related to younger age of onset and to alco-
hol and substance abuse. Following this fact, the World
Health Organization (WHO) has recently ranked bipolar
disorder among the 10 most disabling medical condi-
tions worldwide [7].
Today we know that the treatment of bipolar illness is
complex and full of caveats for the clinician [8-11], with
some aspects of the disorder being rather refractory to
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treatment. One widespread concept among clinicians is
that of the so-called ‘class effect’. As most pharmaceuti-
cal agents belong to a ‘class’ usually on the basis of their
primary therapeutic labeling (for example, antipsycho-
tics, anticonvulsants, antidepressants and so on), it
seems that clinicians use them according to the ‘class’
they belong rather than on the basis of the individual
substance and its properties. This means that the whole
‘class’ of drugs is considered to possesses a specific ther-
apeutic action that in some cases has been proven only
for a few of its members or even only for a single one.
An example in the case of BD could be that all ‘antiepi-
leptics’ are also ‘mood stabilizers’. Clinicians and
researchers seem to treat agents in a ‘class’ way, by, for
example, suggesting that antidepressants do not work in
bipolar depression in spite of the fact that negative data
exist only for a few of them while positive data might
exist for fluoxetine.
If such a situation exists, and patients usually receive
treatment according to a ‘class effect’, it has huge impli-
cations for public health and also for the overall cost of
mental disorders, and especially for bipolar disorder.
The ‘class effect’ provides the clinician with fast and
simple rules to determine treatment, but in the case of
bipolar disorder it might provide the clinician with over-
simplified and false rules, and might result in a signifi-
cant proportion of patients receiving the wrong
treatment.
The present work aims to determine whether such
‘class effects’ are present in bipolar disorder. On the
basis of available evidence, several reviews and meta-
analysis papers [12-16] developed tables concerning the
efficacy of various agents in the different faces and
facets of bipolar illness (Table 1). The question was
whether these tabulated data support or call into ques-
tion the presence of a ‘class effect’ for the treatment of
bipolar disorder.
Methods
We reviewed the available treatment data from rando-
mized controlled trials (RCTs). These treatment datasets
have already been published previously [12-16], so only
minor additions were necessary. Four classes of agents
were examined: first-generation antipsychotics (FGAs),
second-generation antipsychotics (SGAs), antiepileptics
and antidepressants, with respect to their efficacy on
four treatment issues of BD (acute mania, acute bipolar
depression, maintenance against mania, maintenance
against depression). This led to a 4 × 4 crosstabulation
with 16 ‘agent class’/’treatment issue’ cases.
Although such tables already exist in previous works,
we created a new one on the basis of a fresh look at the
available data. In spite of a ‘general acceptance’ of treat-
ment options for bipolar disorder, the evidence shows a
much different picture. Thus, a review of the literature
was judged to be necessary. If the opposite were the,
case the table would rely on arbitrary opinion and could
be misleading.
Results
Effective treatments for bipolar disorder
Valproate has proven efficacy against acute mania
[17-22]. There are only two small positive studies sug-
gesting it might be effective in reducing the symptoms
of depression and anxiety in bipolar I patients during
the acute depressed episode [23,24], (two more on the
extended release form of valproate, one positive and one
negative, have not been published [25,26]). One mainte-
nance phase RCT was negative for valproate, however, it
possibly suffered from a problematic study sample [27].
Carbamazepine is efficacious against acute mania
[28-31], but with regard to acute bipolar depression
there is only one dated positive small withdrawal study
[28] and this is also the case for maintenance [32].
Lamotrigine is not effective against acute mania (two
unpublished negative RCTs exist; SCAA2008 and
SCAA2009) [16] and its efficacy in acute bipolar depres-
sion is controversial (five RCTs were negative on the
primary outcome; SCA100223, SCA30924, SCA40910,
SCAA2010 and SCAB2001 [33]; however, one of those
was clearly positive on the Montgomery-Åsberg Depres-
sion Rating Scale (MADRS) [34] and the only adjunctive
RCT was positive when lamotrigine was combined with
lithium [35]. In contrast, there is strong evidence that
during the maintenance phase, lamotrigine protects
from depressive episodes but not from mania [36-40].
The data concerning the acute manic phase are nega-
tive for gabapentin [41] and topiramate [42].
There are some data concerning the efficacy of FGAs
against acute mania but there are no data against bipo-
lar depression or the maintenance phase. There is only
one early, small, placebo-controlled study supporting the
efficacy of chlorpromazine [43]. Several studies support
the efficacy of haloperidol [44-48]. Most clinicians and
experts believe that typical antipsychotics induce the
opposite pole and cause dysphoria and depression. How-
ever, this has only been reported concerning haloperidol
and perphenazine, suggesting that they could decrease
the time to switch into depression compared with atypi-
cal antipsychotics [49,50].
There are data supporting the efficacy of most SGAs
against acute mania. However, data against acute bipolar
depression and concerning maintenance are not
homogenous.
Olanzapine has proven efficacy against acute mania
[51-55]. Although there are also positive data concern-
ing acute bipolar depression [56] there is concern on
the effect on the ‘depressive core’ of symptoms although
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it is certain that the patients manifested a significant
improvement in symptoms ‘peripheral’ to the definition
of depression such as insomnia, anxiety, loss of appetite
and so on [57,58]. Maintenance data are positive con-
cerning protection from manic, depressive and mixed
episodes with olanzapine [59,60] and with olanzapine-
fluoxetine combination (OFC) [56,61-64].
Quetiapine has proven efficacy against acute mania
[45,65,66], including an unpublished study
(NCT00309699). The data are solid also against acute
bipolar depression [67-74] and they are also effective
against depression in bipolar II depression [75]. Combi-
nation data with a mood stabilizer and monotherapy are
available concerning the maintenance phase [76,77].
Aripiprazole is efficacious against acute mania [78-80]
although one RCT with a fixed dosage design was nega-
tive [81]. Data are negative concerning bipolar depres-
sion [82]. During the maintenance phase it is reported
to protect from manic relapses but not from depressive
relapses [83,84]. Risperidone is efficacious against acute
mania [46,85-87]. Recently, positive data concerning the
maintenance phase became available for long-acting
injectable risperidone, suggesting it is effective in the
prevention of manic or mixed episodes but not depres-
sive episodes [88]. Ziprasidone is efficacious against
acute mania [48,89-91]. Data are negative concerning
bipolar depression (two unpublished studies). There is
one positive maintenance RCT with ziprasidone as an
adjunct to valproate or lithium [92]. Asenapine is effica-
cious against acute mania [54,93]. No data are available
concerning bipolar depression or the maintenance
phase. The data are also positive for paliperidone against
acute mania (one positive RCT with flexible dosage
(NCT00309699) [94] and one negative with fixed dosage
(NCT00299715)), but no data are available concerning
bipolar depression or the maintenance phase.
The use and usefulness of antidepressants in bipolar
disorder is controversial because of the risk of inducing
Table 1 Monotherapy data on the efficacy of agents and classes of agents in different phases of bipolar illness
Agent/modality (alphabetical
order)






FGAs Class effect Unknown Uncertain class effect Unknown
Chlorpromazine Positive - - -
Haloperidol Positive - - -
Perphenazine - - Negative -
SGAs Class effect No class effect Class effect No class effect
Amisulpride - - - -
Aripiprazole Positive Negative Positive Negative
Asenapine Positive - - -
Clozapine Positive - - -
Olanzapine Positive Equivocal Positive Positive
Olanzapine-fluoxetine combination - Positive - -
Paliperidone Positive - - -
Quetiapine Positive Positive Positive Positive
Risperidone Positive - Positive -
Ziprasidone Positive - Positive -
Antiepileptics No class
effect
No class effect No class effect No class effect
Carbamazepine Positive Equivocal Equivocal Equivocal
Gabapentin Negative - - -
Lamotrigine Negative Negative Negative Positive
Licarbazepine Negative - - -
Topiramate Negative - - -
Valproate Positive Equivocal Equivocal Equivocal
Antidepressants Unknown No class effect Unknown No class effect
Fluoxetine - Positive - Positive
Paroxetine - Negative - -
Venlafaxine - Equivocal - -
- = No data available.
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the opposite pole. By definition, antidepressants are not
used against acute mania (and there are no trials during
the acute manic phase). From RCTs against acute bipo-
lar depression, older studies suggested that amitriptiline
[95] and maybe imipramine could be effective [96-98],
with data being somewhat stronger for fluoxetine (parti-
cularly in bipolar II patients) [99-102]. As mentioned
above, data are strong only for OFC [56,62-64]. At the
same time, the data are negative for paroxetine mono-
therapy [103] and equivocal for venlafaxine, possibly
because of a high switch rate [104]. A recent large, nat-
uralistic study showed that up to 15% of the patients
with mania receive antidepressants combined with anti-
manic agents, but this practice was actually associated
with poorer outcomes compared to those who did not
receive antidepressants [105].
Fluoxetine was reported to be effective during the
maintenance phase for bipolar II patients [100,101,106].
The data concerning combination and add-on treat-
ment suggest that in acutely manic patients who are
partial responders to lithium, valproate or carbamaze-
pine, a good strategy would be to add haloperidol,
risperidone, olanzapine, quetiapine or aripiprazole.
Adding oxcarbazepine to lithium could also be a
choice [107-124]. Combination data are negative for
paliperidone (NCT00309686), positive for asenapine
(NCT00145470 and NCT00145509) and negative for
licarbazepine. Combination treatment studies in bipolar
depression are equivocal [35,96-98,103,115,125-131].
A recent unpublished add-on study with ziprasidone
(NCT00483548) was negative. Combination treatment
during the maintenance phase includes quetiapine plus
a mood stabilizer [76,77]; a discontinuation study on
olanzapine as added on lithium or valproate was positive
for olanzapine [132], and another discontinuation RCT
of the combination of mood stabilizer plus ziprasidone
was positive for ziprasidone [92]. Valproate was more
effective than lithium when added on antidepressants
for the prevention of bipolar depression [133].
A 40-week placebo controlled study of the safety and
efficacy of asenapine when added to lithium or valproate
(NCT00145509) and a 40-week extension study of ase-
napine vs olanzapine (Ares 7501007) have also been
conducted.
Generally, add-on studies suggest that at least some
strategies could be useful in patients with inadequate
response to monotherapy. However the recently pub-
lished BALANCE study could neither reliably confirm
nor refute a benefit of combination therapy compared
with lithium monotherapy [134] at least partially
because of methodological flaws [135]. Overall, there is
no compelling data that combination treatment does
better than monotherapy. However, patients stabilized
on combination treatment might do worse if shifted to
monotherapy, and patients refractory to monotherapy
could benefit with add-on treatment with olanzapine,
aripiprazole, risperidone, quetiapine, ziprasidone, valpro-
ate, an antidepressant or lamotrigine, usually depending
on the index acute phase.
A summary of the efficacy of various agents against
the different phases of bipolar illness is shown in
Table 1.
Discussion
In the current study, from the 16 ‘agent class’/’ treat-
ment issue’ cases, only 3 possible class effects were
detected. They all concern acute mania and antipsycho-
tics (FGAs and SGAs against acute mania and SGAs in
maintenance protecting from mania). Four effect cases
are not adequately studied (FGAs against acute bipolar
depression and in maintenance protecting from depres-
sion, antidepressants against acute mania and protecting
from mania) and they all concern treatment cases with
high risk of switching to the opposite pole; thus,
research in these areas is poor.
What is impressive is the lack of any class effect con-
cerning antiepileptics. This has been reported previously
[136], and it is very interesting because anecdotal
reports suggest that the average clinician considers the
term ‘antiepileptic’ to be more or less interchangeable
with ‘mood stabilizer’. However, the data are only posi-
tive concerning valproate, carbamazepine and lamotri-
gine, and only against specific phases of the illness.
From a clinical point of view, depression and the
maintenance phase seem to be more important since
effective treatments are much fewer in comparison to
acute mania. In particular, for the prevention of bipolar
depressive episodes, the options seem to be quite lim-
ited, and no class effect is present.
Pharmacoepidemiological data are limited and usually
concern established treatments such as lithium, valpro-
ate or antipsychotics, but they rarely concern non-
established treatments such as newer antiepileptics. The
lack of this kind of data is especially problematic for
bipolar depression. An unpublished poster presentation
from Japan reported that Japanese psychiatrists were
divided between antidepressants and ‘mood stabilizers’
on the treatment of bipolar depression [137]. A study
from the 1990s utilized the pharmacy records of
McLean Hospital from 1987 to 1993 and reported that
3,829 bipolar depressive inpatients had received tricyclic
antidepressants, 2,981 fluoxetine, 2,603 trazodone, 809
bupropion, 743 monoamine oxidase inhibitors, 592 sti-
mulants, 588 sertraline, 48 paroxetine, and 894 electro-
convulsive therapy [138]. Reports on real-world
maintenance treatment suggest a variable picture. Base-
line treatment data for the first 500 patients in the Sys-
tematic Treatment Enhancement Program for Bipolar
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Disorder (STEP-BD) study (1998 to 1999) revealed that
while standard mood stabilizers (lithium, valproate, or
carbamazepine) were the most commonly prescribed
class of drugs for participants (71.9%), the use of novel
anticonvulsants was high (31.8%) and more frequent
than that of SGAs (27.2%) [139]. Antidepressants are
also prescribed as if there is a ‘class effect’ present dur-
ing the maintenance phase. The US data from non-hos-
pitalized subjects with bipolar I disorder in 1995/1996
suggested that more than half of all subjects were
receiving concomitant antidepressants, of whom nearly
50% received selective serotonin reuptake inhibitor
(SSRI) antidepressants and nearly 25% received bupro-
prion [140]. The data from the 2002 to 2003 US
national MarketScan research databases data suggest
that the most commonly prescribed first drug class was
antidepressants (50% of patients) [141]. Baseline treat-
ment data for the first 500 patients in the STEP-BD
study (1998 to 1999) revealed that the second most
common class of agents was antidepressants (40.6%)
[139]. In The Netherlands, the search of prescription
patterns during 1996 to 2005 revealed a significant
decrease in the use of tricyclic antidepressants, which,
however, were still in wide use [142]. A Hungarian
study reported that 35% of patients were on antidepres-
sants and more than half of them on SSRIs, which
implies a sustained wide use of tricyclics [143]. UK data
from the case note review of patients from north-east
England suggested that 23% of patients were on antide-
pressants; 11% of them were not prescribed a mood sta-
bilizer and 43% of antidepressants prescribed were
tricyclics [144]. Taking the above together, it seems that
depending on the sample, 25% to 50% of bipolar
patients are cross-sectionally under antidepressants, with
almost half of them receiving tricyclics.
It is true that the earlier studies tended to suggest a
high and global effectiveness for older agents on all
facets of bipolar disorder and a high prevalence of
switching with antidepressants. Neither conclusion is
confirmed by newer studies; however, since these con-
clusions were widely accepted for decades, these old
agents are considered to be the ‘gold standard’ and
‘class effects’ were suggested to exist. The extent to
which these ‘class effects’ truly influence everyday clini-
cal practice worldwide is unknown; similarly the extent
they influence the outcome of the treatment and the
natural history of the disease is also unknown.
While evidence-based medicine has seemed to domi-
nate medical scientific thinking in the last few decades,
this is not true for wider clinical practice. The evidence
is limited and hard to interpret and to carry over into
everyday practice. However, it is highly likely that a sig-
nificant number of patients worldwide are not receiving
proper treatment simply because the ‘class effect’ idea
discourages continued scientific training and reading.
Focused educational intervention may be necessary to
change this attitude.
Conclusions
In the treatment of bipolar disorder, a pharmaceutical
class effect is the exception rather than the rule, and
such class effects concern only acute mania and antipsy-
chotics. Some facets of bipolar disorder have not been
adequately studied to date; however, this does not seem
to have influenced the general picture. Since a presumed
‘class effect’ is a very frequent and not adequately stu-
died factor behind pharmaceutical prescription, the
results of the current study suggest that a significant
number of patients worldwide may not receive proper
treatment. This situation can be corrected only by edu-
cational intervention, focused on changing this
misconception.
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